XNASBHST
Market cap106mUSD
Jan 08, Last price
6.15USD
1D
-0.32%
IPO
6.96%
Name
Bioharvest Sciences Inc
Chart & Performance
P/E
—
P/S
8.41
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
102.52%
Rev. gr., 5y
95.04%
Revenues
13m
+130.48%
Net income
-13m
L+11.82%
CFO
-9m
L-7.78%
Earnings
Apr 28, 2025
Profile
BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally. Its plant cell growth technology produces the active secondary metabolites without the need to grow the plant itself. The company designs, develops, manufactures, and markets Vinia, a red grape powder nutraceutical product; and medical cannabis. BioHarvest Sciences Inc. is based in Vancouver, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑04 | 2018‑12 | 2018‑04 | 2017‑04 | 2016‑04 | 2015‑04 | |
| Income | |||||||||||
Revenues | 12,672 130.48% | 5,498 161.56% | |||||||||
Cost of revenue | 22,482 | 15,939 | |||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (9,810) | (10,441) | |||||||||
NOPBT Margin | |||||||||||
Operating Taxes | (861) | ||||||||||
Tax Rate | |||||||||||
NOPAT | (9,810) | (9,580) | |||||||||
Net income | (12,564) 11.82% | (11,236) 14.34% | |||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | 20,916 | 8,888 | |||||||||
Long-term debt | 3,233 | 3,679 | |||||||||
Deferred revenue | 2,010 | ||||||||||
Other long-term liabilities | 1,963 | 123 | |||||||||
Net debt | 18,794 | 10,610 | |||||||||
| Cash flow | |||||||||||
Cash from operating activities | (8,522) | (9,241) | |||||||||
CAPEX | (1,474) | (1,256) | |||||||||
Cash from investing activities | (1,474) | (1,256) | |||||||||
Cash from financing activities | 13,556 | 8,138 | |||||||||
FCF | (9,820) | (10,977) | |||||||||
| Balance | |||||||||||
Cash | 5,355 | 1,736 | |||||||||
Long term investments | 221 | ||||||||||
Excess cash | 4,721 | 1,682 | |||||||||
Stockholders' equity | (14,853) | (5,929) | |||||||||
Invested Capital | 24,304 | 12,691 | |||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 13,533 | 13,054 | |||||||||
Price | 7.53 2,496.55% | 0.29 -36.96% | |||||||||
Market cap | 101,905 2,591.93% | 3,786 -33.89% | |||||||||
EV | 120,699 | 14,396 | |||||||||
EBITDA | (8,970) | (9,729) | |||||||||
EV/EBITDA | |||||||||||
Interest | 936 | 1,399 | |||||||||
Interest/NOPBT | |||||||||||